{"entity":{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","aka":[],"tldr":"The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).","summary":"Ga-68 DOTATATE (Netspot, kit) approved June 2016; Cu-64 DOTATATE (Detectnet, 12.7-hour half-life allows central production) approved September 2020; Ga-68 DOTATOC (2019, academic). Changes management in about a third of patients; required before Lu-177 DOTATATE (Lutathera). Also images meningioma and paraganglioma.","status":"approved","asOf":"2026-09-08","links":[{"label":"Label: Netspot (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Netspot"},{"label":"Label: Detectnet (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Detectnet"}],"tags":["gap-fill","diagnostic"],"related":["ga-68","cu-64","lu-177"],"indications":["neuroendocrine","small-intestinal-net","pancreatic-net","lung-net"],"sections":[],"technologies":["sstr-pet","pet-ct","prrt","radioligand-therapy"],"targets":["sstr2"],"drugs":[],"companies":["novartis","curium"],"institutions":[],"pathways":[],"terms":["theranostics","prrt-term"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Netspot / Detectnet","modality":"PET radiotracer (somatostatin receptor ligand)","mechanism":"Radiolabelled somatostatin analogue binding SSTR2 on neuroendocrine tumours; PET replaces the older In-111 octreotide SPECT with higher sensitivity and same-day imaging.","approvals":[{"region":"US","year":2016,"indication":"PET localisation of SSTR-positive neuroendocrine tumours (Ga-68 DOTATATE)"},{"region":"US","year":2020,"indication":"Same (Cu-64 DOTATATE)"},{"region":"EU","year":2017,"indication":"SomaKit TOC (Ga-68 DOTATOC)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ga68-dotatate/","neighbours":{"isotope":[{"id":"cu-64","kind":"isotope","name":"Copper-64","route":"/isotopes/cu-64/"},{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/"},{"id":"ge-68","kind":"isotope","name":"Germanium-68","route":"/isotopes/ge-68/"},{"id":"in-111","kind":"isotope","name":"Indium-111","route":"/isotopes/in-111/"},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}],"indication":[{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/"},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/"}],"technology":[{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/"},{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/"},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/"},{"id":"sstr-pet","kind":"technology","name":"Somatostatin receptor PET (68Ga/64Cu-DOTATATE)","route":"/technologies/sstr-pet/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"},{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}],"term":[{"id":"krenning-score","kind":"term","name":"Krenning score","route":"/terms/krenning-score/"},{"id":"prrt-term","kind":"term","name":"PRRT (peptide receptor radionuclide therapy)","route":"/terms/prrt-term/"},{"id":"theranostic-pair-term","kind":"term","name":"Theranostic pair","route":"/terms/theranostic-pair-term/"},{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/"}],"opportunity":[{"id":"opp-cardiac-sarcoidosis-specific-tracer","kind":"opportunity","name":"An inflammation tracer that does not need a diet","route":"/opportunities/opp-cardiac-sarcoidosis-specific-tracer/"}],"drug":[{"id":"cu-64-dotatate","kind":"drug","name":"Copper-64 dotatate","route":"/drugs/cu-64-dotatate/"},{"id":"ga-68-dotatoc","kind":"drug","name":"Gallium-68 edotreotide (DOTATOC)","route":"/drugs/ga-68-dotatoc/"},{"id":"in-111-pentetreotide","kind":"drug","name":"Indium-111 pentetreotide","route":"/drugs/in-111-pentetreotide/"}],"bottleneck":[{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/"}],"section":[{"id":"f-molecular-imaging","kind":"section","name":"Molecular imaging","route":"/fronts/f-molecular-imaging/"}],"pairing":[{"id":"ga68-dotatate-then-lutathera","kind":"pairing","name":"68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)","route":"/pairings/ga68-dotatate-then-lutathera/"}],"roadmap":[{"id":"neuro-imaging-roadmap","kind":"roadmap","name":"Neuro-oncology imaging roadmap: FDG PET → amino acid PET → SSTR2 theranostics in meningioma","route":"/roadmaps/neuro-imaging-roadmap/"},{"id":"sstr-theranostics-roadmap","kind":"roadmap","name":"SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha","route":"/roadmaps/sstr-theranostics-roadmap/"}]}}